Fidelity SPDR Advertisement
Home > Boards > US Listed > Medical - Drugs >

Transgenomic Inc. (TBIO)

TBIO RSS Feed
Add TBIO Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator
Search This Board:
Last Post: 5/8/2014 11:12:57 AM - Followers: 13 - Board type: Free - Posts Today: 0

Home

Link to coporate website:
http://www.transgenomic.com/

TICKER SYMBOL:TBIO
Share Structure
Market Value1 $40,142,705 a/o May 10, 2013
Shares Outstanding 88,225,725 a/o Mar 13, 2013
Float Not Available
Authorized Shares 100,000,000 a/o Aug 02, 2011
Par Value 0.01

TRANSFER AGENT:
Wells Fargo Bank Minnesota, N.A.
Shareowner Services
P.O. Box 64854
St. Paul, MN 55164-0854
Phone: 877-602-7611

About:
Transgenomic is a global biotechnology company that provides unique products and services for automated high sensitivity genetic variation and mutation analysis. Our offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine.

Transgenomic offers its WAVE® DHPLC Systems and associated consumables. These systems are specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification and have broad applicability to genetic research. To date there have been over 1600 systems shipped to more than 30 countries.

Transgenomic's SURVEYOR® Mutation Detection Kits and the SURVEYOR Check-It Kit provide reagents and protocols for the detection of mutations in DNA.

Transgenomic's Cytogenetics offering includes HANABI automated chromosome harvesting systems that improve laboratory productivity with consistent quality compared to manual methods.

Transgenomic Clinical Reference Laboratory provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases.

Transgenomic Genomic Research Services is a CRO for pharmacogenomic, translational research and clinical trials.



Colorectal Cancer Testing



Very important AMGEN signs collaberation deal with Mgmt:

"Another potential meaningful near-term contributor to the Lab Services segment (as well as to the Diagnostic Tools segment) relates to the recently consummated agreement with Amgen (NasdaqGS:AMGN) whereby the two companies are collaborating on a KRAS an NRAS gene mutation assay kit to screen patients for colorectal cancer.  The RAScan test is currently available for research use only (RUO) in the U.S. (which will run through Lab Svcs) and for clinical use in Europe - which could help accelerate instrument placements (through Menarini) as well as increase consumables sales"



CRC RAScan™ is a new mutation detection test designed to screen for selected KRAS and NRAS mutations (collectively referred to as “RAS mutations”), in patients with metastatic colorectal cancer (mCRC).The identification of these RAS mutations can give physicians important clinical information to help them make better treatment decisions for their mCRC patients.

KRAS and NRAS are part of the RAS family of genes which encode proteins involved in transmitting signals within cells. When Ras proteins are “switched on” by incoming signals, other genes involved in cell growth, differentiation, and survival are activated. Mutations in KRAS, NRAS and other related genes can lead to Ras proteins becoming permanently activated, causing overactive signaling even in the absence of incoming signals, and can lead to the uncontrolled cell growth that characterizes cancer. Mutations that permanently activate Ras proteins are found in ~25% of human tumors and up to 90% of certain cancers. About 40% of colorectal tumors carry KRAS gene mutations and these mutations have been associated with poor response to EGFR antagonists such as cetuximab and panitumumab. Therefore KRAS mutation status can be used to determine whether or not a patient with colorectal cancer will respond to anti-EGFR therapy.

The CRC RAScan test can identify mCRC patients who have RAS mutations at levels that cannot be detected using traditional Sanger Sequencing methods.

CRC RAScan™ for Colorectal Cancer Tumor Testing is available immediately from Transgenomic’s CLIA-certified laboratory in the United States. For more information on this test, click here.

CRC RAScan Mutation Detection Kits will soon be available in the U.S for research use only. CRC RAScan Mutation Detection Kits include the following kits based on Transgenomic's proprietary SURVEYOR® Nuclease technology:

  • KRAS Exon 2
  • KRAS Exons 3 & 4
  • NRAS Exons 2, 3 & 4

Zacks analyst ~ OUR 2013 OUTLOOK~

We've again made some updates to our model.  We now model 2013 revenue of $32.4 million, implying growth of 3% from 2012.  We look for Laboratory Services and Instruments to generate revenue of $20.0 million (+4%) and $12.4 million (+2%), respectively.  We think net income and EPS come in at ($12.7) million and ($0.14).


2013 ASCO CONFERENCE ABSTRACT

http://www.amgen.com/media/media_pr_detail.jsp?year=2013&releaseID=1820728




May. 15, 2013 AMGEN PRESS RELEASE
New Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer

Biomarker Analysis From Phase 3 PRIME ('203) Study and Phase 2 PEAK ('509) Study Link Additional RAS Gene Mutations to Vectibix Clinical Response

THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from three analyses of Vectibix® (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as a first-line treatment for metastatic colorectal cancer (mCRC). These analyses include the description of new predictive biomarkers of clinical response to Vectibix, activating mutations in KRAS (beyond exon 2) and mutations in NRAS, collectively referred to as RAS.

"Amgen helped establish KRAS gene mutation as a biomarker for lack of response to anti-EGFR treatment," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "The identification of new biomarkers may further help to identify appropriate patients with this incurable disease for such treatment."

 









Contact Information:
Phone: (402) 452-5437
E-mail: investorrelations@transgenomic.com

SEC Filings:
http://www.nasdaq.com/asp/quotes_sec.asp?page=filings&symbol=TBIO&selected=TBIO&rpage=sec&


Press Releases:
http://finance.yahoo.com/q?s=TBIO.OB








   
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TBIO
Current Price
Volume:
Bid Ask Day's Range
Wiki
TBIO News: Current Report Filing (8-k) 07/02/2014 04:25:15 PM
TBIO News: Current Report Filing (8-k) 07/02/2014 06:01:29 AM
TBIO News: Securities Registration: Employee Benefit Plan (s-8) 06/12/2014 05:25:04 PM
TBIO News: Initial Statement of Beneficial Ownership (3) 05/29/2014 04:01:00 PM
TBIO News: Amended Statement of Ownership (sc 13g/a) 05/28/2014 01:10:54 PM
PostSubject
#310   Listing to Nasdaq Friday! Marvy 05/08/14 11:12:57 AM
#309   S.B.A., I have been following Jenne for two cloveless0976 02/15/14 10:54:54 PM
#308   Renee, This is a very good sign, I went cloveless0976 02/15/14 10:47:50 PM
#307   TBIO one for 12 reverse split: Renee 01/27/14 04:49:59 PM
#306   TBIO Video Chart 12/16/13 MissionIR 12/16/13 11:54:34 AM
#305   pssst... keep this under yre hat <bg> Old Hillbilly 10/15/13 05:29:44 PM
#304   I like these "under the I hub BS" Old Hillbilly 09/16/13 11:50:36 AM
#303   just home buying this and more arwr tomorrow JUST 10-11-12 08/08/13 04:56:18 PM
#302   Quest Diagnostics Introduces Comprehensive Opioid Therapy Genetic Test ~S.B.A.~ 08/08/13 04:04:50 PM
#301   Great News out ! ~S.B.A.~ 08/08/13 04:02:01 PM
#300   Another Stockboardassets dog! Great work! alexwv 07/24/13 04:51:19 PM
#299   70000 shares by NITE at .47 on the gator16 07/23/13 11:51:48 AM
#298   On a rip will jump in if support ~S.B.A.~ 07/23/13 08:23:37 AM
#297   this is showing signs Roy London 07/22/13 11:45:26 PM
#296   ~ $TBIO ~ Daily Par Sar Buy Signal Penny Roger$ 07/22/13 10:27:46 PM
#295   Someone is buying a ton of TBIO today gator16 07/15/13 01:33:21 PM
#294   still looks like .35 then .30 to me.....good luck etradeedge 06/04/13 12:22:08 PM
#293   looks like the market answered my question. Dead gator16 06/04/13 09:43:20 AM
#292   How do you view the news. Low Med gator16 06/04/13 08:10:40 AM
#291   http://finance.yahoo.com/news/transgenomic-apocell-present-results-lung-14300096 ~S.B.A.~ 06/03/13 08:42:26 PM
#290   38.2% fib retrace touched. Healthy trading as we ~S.B.A.~ 06/03/13 07:55:06 PM
#289   Agreed, sell-off today, but large bids in the ~S.B.A.~ 06/03/13 03:42:39 PM
#288   oscillators are coming off the wheels gator16 06/03/13 02:05:10 PM
#287   It's over gator16 06/03/13 12:37:34 PM
#286   The oscillators are coming off support and are ~S.B.A.~ 06/02/13 09:32:04 PM
#285   Low Volume here on TBIO and downward intraday alexwv 06/01/13 10:11:11 AM
#284   CHART SCREENSHOT. ~S.B.A.~ 05/31/13 06:36:10 PM
#283   This company has the only test mutation kits ~S.B.A.~ 05/31/13 10:11:24 AM
#282   Thanks. While the deal with Amgen is murocman 05/31/13 09:27:18 AM
#281   MAY 8, 2013 CC LINK ~S.B.A.~ 05/31/13 09:26:00 AM
#280   Review the CC as they are commercializing their ~S.B.A.~ 05/31/13 09:11:59 AM
#279   What is new/unknown about Transgenomic's tests being used murocman 05/31/13 07:35:38 AM
#278   To the moon ladies and gentlemen, to the StockWizard 05/31/13 04:43:18 AM
#277   Should see PR soon regarding ASCO! Time for PSFlyer 05/30/13 06:46:20 PM
#276   Nice Correction trend reversal forming. Looking for big ~S.B.A.~ 05/30/13 02:24:07 PM
#275   It would be wise for MGMT to PR ~S.B.A.~ 05/30/13 10:52:51 AM
#274   Fib retrace screenshot holding above 61.8% very healthy. ~S.B.A.~ 05/29/13 04:11:22 PM
#273   Low volume, i beg to differ with your ~S.B.A.~ 05/29/13 03:48:54 PM
#272   just starting to drop 35 cents next target etradeedge 05/29/13 03:40:21 PM
#271   Keep in mind more details about AMGEN deal ~S.B.A.~ 05/29/13 03:37:09 PM
#270   When MGMT drops the ASCO conference PR that ~S.B.A.~ 05/29/13 03:35:40 PM
#269   I hope you are correct but I don't gator16 05/29/13 03:26:13 PM
#268   50%fib retrace. Healthy consolidation. Low volume ~S.B.A.~ 05/29/13 02:50:23 PM
#267   Down 5 cents gator16 05/29/13 02:45:05 PM
#266   Its called patience and you'll beat the market ~S.B.A.~ 05/29/13 11:02:40 AM
#265   God luck everybody . I for one don't gator16 05/29/13 10:57:46 AM
#264   Agreed, once MGMT releases pr about ASCO meeting, ~S.B.A.~ 05/28/13 12:33:21 PM
#263   It sure is under the radar gator16 05/28/13 11:26:37 AM
#262   Keep praying. usually some news would have leaked. gator16 05/28/13 11:08:47 AM
#261   Agreed, this gem still under the radar, I PSFlyer 05/28/13 08:42:57 AM
PostSubject